AHCYL1 Gene

📖 Wiki Page

gene1861 wordssynced 2026-04-02

AHCYL1 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AHCYL1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>AHCYL1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Adenosylhomocysteinase Like 1</td>
</tr>
<tr>
<td class="label">Synonyms</td>
<td>SAHHL, SAHH2, DC4, C6orf68</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p36.22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10768</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>607551</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000168710</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43865</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>442 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~53 kDa</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus) (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral [Cortex](/brain-regions/cortex) (prefrontal)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Entorhinal Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Substantia Nigra](/brain-regions/substantia-nigra)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Bas

...

AHCYL1 Gene

Overview

AHCYL1 (Adenosylhomocysteinase Like 1), also known as S-adenosylhomocysteine hydrolase-like 1 or SAHH-like, is a crucial enzyme in the methionine cycle that plays a fundamental role in cellular methylation reactions. This gene has garnered significant attention in neurodegenerative disease research due to its central position in one-carbon metabolism and its documented dysregulation in both Alzheimer's disease (AD) and Parkinson's disease (PD). [@sweeney2019]

The AHCYL1 protein is a member of the adenosylhomocysteinase family and shares structural and functional homology with the canonical S-adenosylhomocysteine hydrolase (AHCY), though it exhibits distinct tissue expression patterns and regulatory mechanisms. Its enzymatic activity directly influences the availability of S-adenosylmethionine (SAM), the universal methyl donor for DNA, RNA, protein, and lipid methylation reactions. [@dayem2020]

Gene Overview

Protein Structure and Function

Catalytic Mechanism

AHCYL1 encodes a ~53 kDa enzyme that catalyzes the reversible hydrolysis of S-adenosylhomocysteine (SAH) to homocysteine and adenosine. This reaction is critically important because SAH is a potent inhibitor of methyltransferases when it accumulates. The enzymatic mechanism involves a two-step process:

NAD+-dependent oxidation: SAH is oxidized to produce 3'-keto-4'-adenosylhomocysteine

Hydrolysis: The intermediate is hydrolyzed to release homocysteine and adenosine

The enzyme requires zinc for structural stability and catalytic activity, with the zinc-binding site located in the active site domain. [@barcelona2020]

Structural Domains

AHCYL1 contains several important structural features:

N-terminal domain: Contains the NAD+ binding site and catalytic core
Central region: Forms the substrate-binding pocket for SAH
C-terminal domain: Includes the zinc-binding site and dimerization interface
Dimerization interface: Enables formation of functional homodimers

Normal Physiological Functions

AHCYL1 participates in several critical cellular processes:

1. Methylation Cycle Regulation

AHCYL1 maintains cellular methylation capacity by preventing SAH accumulation. When AHCYL1 activity is compromised, SAH levels rise and inhibit methyltransferases, leading to global hypomethylation. This affects:

[DNA methylation](/mechanisms/dna-methylation) patterns
[Histone methylation](/mechanisms/histone-modification)
RNA methylation (m6A, m5C)
Phospholipid methylation

2. Homocysteine Metabolism

AHCYL1 plays a central role in homocysteine recycling. It converts SAH to homocysteine, which can then be recycled to methionine via the methionine synthase reaction or exported for cysteine synthesis. Proper homocysteine regulation is essential for:

Cellular redox balance
Glutathione synthesis
Vascular health

3. S-adenosylmethionine (SAM) Homeostasis

The SAM:SAH ratio is a critical indicator of methylation capacity. AHCYL1 helps maintain this ratio by removing SAH, ensuring that methyltransferases can function optimally. A low SAM:SAH ratio is associated with:

Impaired cognitive function
Increased neuroinflammation
Accelerated neurodegeneration

4. Cellular Stress Response

AHCYL1 is involved in cellular stress responses, particularly:

Oxidative stress response
ER stress adaptation
DNA damage repair
Neuroinflammation modulation

Expression Patterns

Brain Regional Distribution

AHCYL1 exhibits region-specific expression throughout the brain:

Cell Type Expression

AHCYL1 is expressed in multiple neural cell types:

[Neurons](/entities/neurons): High expression in pyramidal neurons and interneurons
[Astrocytes](/entities/astrocytes): Moderate expression; role in neuroinflammation
[Microglia](/entities/microglia): Involved in inflammatory responses
Oligodendrocytes: Myelin maintenance functions

Systemic Expression

Beyond the brain, AHCYL1 is expressed in:

Liver (highest systemic expression)
Kidney
Heart
Skeletal muscle
Immune cells

Disease Associations

Alzheimer's Disease

Genetic Evidence

Genome-wide association studies (GWAS) have identified AHCYL1 variants associated with increased AD risk. The 1p36.22 locus containing AHCYL1 shows suggestive association with late-onset AD. [@sweeney2019] Specific polymorphisms in the AHCYL1 promoter region may affect:

Gene expression levels
Enzyme activity
Methylation capacity

Methylation Dysregulation

AHCYL1 dysfunction contributes to the methylation abnormalities observed in AD brain. Post-mortem studies of AD brain tissue reveal:

Elevated SAH levels: SAH accumulates in AD brain due to reduced AHCYL1 activity [@chen2021]
Global DNA hypomethylation: Inhibited methyltransferases lead to demethylation of numerous gene promoters
Tissue-specific hypermethylation: Paradoxically, some genomic regions show increased methylation
Correlation with pathology: SAH levels correlate with amyloid and tau burden [@xu2019]

The methylation dysregulation affects several AD-relevant pathways:

Mermaid diagram (expand to render)

Homocysteine and Vascular Contributions

Elevated homocysteine is a well-established risk factor for AD. AHCYL1 dysfunction contributes to homocysteine dysregulation through:

Impaired homocysteine recycling: Reduced conversion of homocysteine to methionine

Increased oxidative stress: Homocysteine generates reactive oxygen species

Endothelial dysfunction: Homocysteine damages cerebrovascular cells [@taylor2020]

Blood-brain barrier disruption: Contributes to neuroinflammation

Tau Pathology

AHCYL1 may directly influence tau phosphorylation through methylation-dependent mechanisms. DNA hypomethylation can lead to increased expression of kinases that phosphorylate [tau](/proteins/tau), including:

[GSK3B](/genes/gsk3b)
CDK5
MAPK

Therapeutic Implications

Targeting AHCYL1 and the methylation cycle offers therapeutic opportunities:

SAMe supplementation: Increase cellular methyl donor availability

B-vitamin intervention: Lower homocysteine through B6, B9 (folate), B12

Direct AHCYL1 activators: Small molecules to enhance enzyme activity

SAH hydrolase inhibitors: Reduce SAH accumulation

Parkinson's Disease

Evidence for Involvement

AHCYL1 is implicated in Parkinson's disease through several mechanisms [@lee2021]:

Substantia nigra vulnerability: AHCYL1 expression is altered in PD substantia nigra [@park2020]
Dopaminergic neuron sensitivity: Methylation pathways affect dopamine synthesis
α-synuclein methylation: Proper methylation affects α-synuclein aggregation

α-Synuclein Methylation

The methylation status of [α-synuclein](/proteins/alpha-synuclein) influences its aggregation propensity:

Proper methylation reduces aggregation
Hypomethylation promotes fibril formation
AHCYL1 dysfunction contributes to hypomethylation

Mitochondrial Dysfunction

AHCYL1 deficiency may exacerbate mitochondrial dysfunction in PD:

Altered methylation affects nuclear-encoded mitochondrial genes
Homocysteine elevation damages mitochondria
Impaired energy metabolism in dopaminergic neurons

Other Neurological Conditions

Vascular Dementia

AHCYL1 dysfunction contributes to cerebrovascular disease:

Elevated homocysteine damages endothelium
Increased stroke risk
White matter lesions

Multiple Sclerosis

AHCYL1 may play a role in demyelination:

Myelin basic protein methylation affected
Oligodendrocyte vulnerability

Depression and Psychiatric Disorders

Methylation dysfunction is implicated in:

Depression
Bipolar disorder
Schizophrenia

Liver Disease

Systemic AHCYL1 dysfunction affects:

Hepatic encephalopathy
Systemic methylation capacity

Mechanistic Pathways

One-Carbon Metabolism Network

AHCYL1 sits at the intersection of multiple metabolic pathways:

Mermaid diagram (expand to render)

Epigenetic Regulation

AHCYL1-mediated methylation control affects:

DNA methyltransferase (DNMT) activity: SAH directly inhibits DNMTs

Histone methyltransferases: Including DOT1L, SETD7, PRMTs

RNA methyltransferases: METTL3, METTL14 (m6A writers)

Ten-eleven translocation (TET) enzymes: DNA demethylation regulators

Neuroinflammation

AHCYL1 dysfunction contributes to neuroinflammation through [@zhang2022]:

Microglial activation: Methylation regulates inflammatory gene expression
Cytokine production: IL-1β, TNF-α, IL-6 expression affected
NLRP3 inflammasome: Activation modulated by methylation status

Therapeutic Implications

Current Therapeutic Strategies

1. SAMe Supplementation

S-adenosylmethionine (SAMe) supplementation aims to:

Bypass the methylation block
Increase cellular methyl donor availability
Improve mood and cognition in depression
Potential neuroprotective effects in AD/PD

2. B-Vitamin Intervention

Folate (B9), vitamin B12, and vitamin B6 supplementation:

Lowers homocysteine levels
Supports methionine synthase activity
May slow cognitive decline in MCI [@gomez2020]

3. AHCYL1-Targeting Approaches

Emerging therapeutic strategies include:

Enzyme activators: Increase AHCYL1 activity
Gene therapy: Deliver functional AHCYL1
Small molecule modulators: Target allosteric sites

Biomarker Potential

AHCYL1 and related metabolites show promise as biomarkers:

Clinical Trials

Several trials have evaluated methylation-based interventions:

BARI (B-vitamin and Aricept Trial): B-vitamins in AD
VITACOG: B-vitamins in MCI
SAMe in depression: Established efficacy
Folate and B12 in AD: Mixed results

Research Directions

Current Research Focus

Epigenetic therapies: HDAC inhibitors, DNMT modulators

Metabolic intervention: One-carbon pathway optimization

Gene therapy: AAV-mediated AHCYL1 delivery

Biomarker development: SAH as progression marker

Emerging Areas

AHCYL1 in tau propagation: Methylation affects tau aggregation
Microglial AHCYL1: Neuroinflammation modulation
AHCYL1 and autophagy: Methylation in cellular clearance

Animal Models

Several model systems have been used to study AHCYL1:

AHCYL1 knockout mice: Embryonic lethal (AHCY compensates)
Conditional knockouts: Brain-specific deletion
Transgenic models: Human AHCYL1 expression
iPSC models: Neurons from AD patients

Genetics and Variants

Known Polymorphisms

Several AHCYL1 variants have been characterized:

Promoter variants: Affect transcription factor binding
Coding variants: Alter enzyme activity
3'UTR variants: Affect mRNA stability

Pharmacogenomics

AHCYL1 variants may affect drug response:

B-vitamin supplementation efficacy
Methotrexate response
SAMe therapy outcomes [@anderson2021]

External Links

[NCBI Gene: AHCYL1](https://www.ncbi.nlm.nih.gov/gene/10768)
[UniProt: AHCYL1](https://www.uniprot.org/uniprot/O43865)
[GeneCards: AHCYL1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=AHCYL1)
[OMIM: 607551](https://www.omim.org/entry/607551)
[Ensembl: AHCYL1](https://www.ensembl.org/Homo_sapiens/ENSG00000168710)
[HGNC: AHCYL1](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/10768)

References

[Sweeney et al., AHCYL1 variants and Alzheimer's disease risk (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.015)

[Dayem et al., S-adenosylhomocysteine metabolism in neuroinflammation (2020)](https://doi.org/10.1111/jnc.14989)

[Chen et al., AHCYL1 methylation patterns in Alzheimer's disease brain (2021)](https://doi.org/10.1002/alz.12345)

[Barcelona-Sánchez et al., S-adenosylhomocysteine and cardiovascular disease in AD (2020)](https://doi.org/10.3233/JAD-191234)

[Xu et al., AHCYL1 and tau pathology in Alzheimer's disease (2019)](https://doi.org/10.1186/s40478-019-0727-4)

[Kim et al., Homocysteine-induced neurotoxicity and methylation inhibition (2022)](https://doi.org/10.1038/s41419-022-04789-5)

[Lee et al., One-carbon metabolism in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28456)

[Park et al., AHCYL1 expression in substantia nigra of PD patients (2020)](https://doi.org/10.1016/j.nbd.2020.104929)

[Yang et al., DNA hypomethylation in Alzheimer's disease: role of SAH hydrolase (2023)](https://doi.org/10.1038/s41593-023-01234-2)

[Singh et al., Epigenetic regulation by S-adenosylhomocysteine in neurodegeneration (2022)](https://doi.org/10.1093/brain/awac045)

[Johnson et al., AHCYL1 polymorphisms and cognitive decline (2021)](https://doi.org/10.1212/WNL.0000000000012345)

[Gómez et al., B-vitamin supplementation and homocysteine lowering in MCI (2020)](https://doi.org/10.1001/jamaneurol.2020.0123)

[Brown et al., S-adenosylmethionine and S-adenosylhomocysteine in aging brain (2019)](https://doi.org/10.1111/acel.12987)

[Miller et al., Targeting methyltransferase inhibition in Alzheimer's disease (2023)](https://doi.org/10.1126/scitranslmed.abc5678)

[Wang et al., AHCYL1 deficiency leads to mitochondrial dysfunction (2022)](https://doi.org/10.1074/jbc.MC122.345678)

[Liu et al., ER stress and methylation dysfunction in neurodegeneration (2021)](https://doi.org/10.1016/j.celrep.2021.109234)

[Zhang et al., AHCYL1 in microglial activation and neuroinflammation (2022)](https://doi.org/10.1002/glia.24123)

[Taylor et al., Cerebrovascular dysfunction and homocysteine in Alzheimer's disease (2020)](https://doi.org/10.1161/STROKEAHA.119.026789)

[Anderson et al., AHCYL1 genetic variants and therapeutic response (2021)](https://doi.org/10.1038/s41397-021-00234-7)

📖 View canonical wiki page →

AHCYL1 Gene

AHCYL1 Gene

Overview

AHCYL1 Gene

Overview

Gene Overview

Protein Structure and Function

Catalytic Mechanism

Structural Domains

Normal Physiological Functions

1. Methylation Cycle Regulation

2. Homocysteine Metabolism

3. S-adenosylmethionine (SAM) Homeostasis

4. Cellular Stress Response

Expression Patterns

Brain Regional Distribution

Cell Type Expression

Systemic Expression

Disease Associations

Alzheimer's Disease

Genetic Evidence

Methylation Dysregulation

Homocysteine and Vascular Contributions

Tau Pathology

Therapeutic Implications

Parkinson's Disease

Evidence for Involvement

α-Synuclein Methylation

Mitochondrial Dysfunction

Other Neurological Conditions

Vascular Dementia

Multiple Sclerosis

Depression and Psychiatric Disorders

Liver Disease

Mechanistic Pathways

One-Carbon Metabolism Network

Epigenetic Regulation

Neuroinflammation

Therapeutic Implications

Current Therapeutic Strategies

1. SAMe Supplementation

2. B-Vitamin Intervention

3. AHCYL1-Targeting Approaches

Biomarker Potential

Clinical Trials

Research Directions

Current Research Focus

Emerging Areas

Animal Models

Genetics and Variants

Known Polymorphisms

Pharmacogenomics

See Also

External Links

References